Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
about
Herbal medicines and nonalcoholic fatty liver diseaseMolecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASHGenetic background in nonalcoholic fatty liver disease: A comprehensive reviewRegulation of Ketone Body Metabolism and the Role of PPARαThe Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MicePPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα DeficiencyInterspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontinApple Polyphenols Decrease Atherosclerosis and Hepatic Steatosis in ApoE-/- Mice through the ROS/MAPK/NF-κB PathwayEvaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.Red blood cell count has an independent contribution to the prediction of ultrasonography-diagnosed fatty liver disease.Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.Identification of Haplotype Tag Single-Nucleotide Polymorphisms within the PPAR Family Genes and Their Clinical Relevance in Patients with Major TraumaThe pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis.Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emerging Role of Lipin-1.PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.p21(Cip1) plays a critical role in the physiological adaptation to fasting through activation of PPARα.Hepatic Fasting-Induced PPARα Activity Does Not Depend on Essential Fatty Acids.Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish LarvaeReview article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Cyclin D1 represses peroxisome proliferator-activated receptor alpha and inhibits fatty acid oxidation.MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers.Human Carboxylesterase 2 Reverses Obesity-Induced Diacylglycerol Accumulation and Glucose Intolerance.Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.Dexamethasone Pretreatment Alleviates Isoniazid/Lipopolysaccharide Hepatotoxicity: Inhibition of Inflammatory and Oxidative Stress.MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN.Elucidating fish oil-induced milk fat depression in dairy sheep: Milk somatic cell transcriptome analysis.The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.Collagen peptide ingestion alters lipid metabolism-related gene expression and the unfolded protein response in mouse liver.Molecular mechanisms of fatty liver in obesity.Re-adaption on Earth after Spaceflights Affects the Mouse Liver Proteome.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Nuclear receptors and nonalcoholic fatty liver disease.Management of cholestatic disease in 2017.Novel Pharmacotherapy Options for NASH.Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.The therapeutic landscape of non-alcoholic steatohepatitis.
P2860
Q26738524-3A30BA79-AE1D-432E-A55F-424C87CA7281Q26778376-6018C065-17DF-421D-BDBD-986A535E058EQ26780248-1015EF2F-1CCF-4A5A-9275-B905A99D79EAQ28073224-C212DDC8-7B5C-46C1-97F9-935AB42B39DBQ28552063-C75FEBDE-05B7-45A4-9877-DA13CE9ADE9DQ30241952-E4A26AB9-4FF2-4BDB-A635-1F88DF51353AQ33631584-942D148D-DBF1-4A38-81D1-7BE6BDE25703Q33877800-F998D92F-A5FD-45ED-941C-E5267188AE78Q36012491-83F44F19-E761-4C6B-86EB-0ABD26B55B27Q36159376-9358EEB1-5E3C-4A0F-B057-0265B6413621Q36277177-FC4960C7-76F1-41EA-8FE8-46B7FF1268C1Q36618918-C6EA69BB-076D-4030-9C3D-BB0BAFB64372Q36841634-B00BAA6F-3644-43DC-A465-F85A0CB5A532Q36922236-EC68E969-90A7-41EB-907F-75422B565343Q36932697-071303FB-16D8-4B6D-9E5F-2C221B11EE26Q36939099-BA850E7E-8050-472D-96EA-D71DA68A0EA7Q37323875-3708CED7-BDBB-45D6-981D-C7F3D047EA80Q37377235-7ED07407-B6AD-46BA-B777-6D2880740EEDQ37428683-FF0784E4-DC3E-4851-9F5C-4C8EF1A44BAEQ37563673-FEB641D1-550B-494C-BF25-F6C8432A377EQ37565240-AAE4E5E5-0DBC-4114-BC4B-3082CBD2CBC6Q37607478-0ECDAFC7-246A-4C41-9D24-AE915C96E491Q37611624-370B79EC-4BBB-4FDF-9E4B-0D51EAFF42F6Q37615168-37FA9DCB-7B97-4A11-B133-D8F24A8AF285Q37640263-60F6C4E4-EE74-4DB6-86F0-393D79128CCFQ37691021-66B4D5AA-6B3A-47AB-8E79-60BCFB9EA1F3Q37699610-C5686179-F803-46ED-B16A-5078F025A8D8Q37706642-3553F878-4347-47CF-A911-D7D5D74B4C66Q37737986-7C5D3BDC-3B4D-4FFE-BB37-0688322B3730Q38289759-B8148A66-554F-4F57-A04E-4983F41C96EFQ38438093-17A8C688-840E-4B85-A005-AFFEAA068F92Q38569945-3D928CC4-6A59-400C-BD98-972D6B18DC74Q38626139-D21662AD-FB5D-4B46-8EEC-DFF297BC7C0CQ38713765-32A777A7-13DB-4927-A119-CB780CA893BCQ38752520-3F4B3988-3B8E-49C0-9E1A-EFBE47E7BE18Q38768048-67B7A681-3E57-428D-9403-1DF5645072DBQ38774857-6C395D40-B3DE-4523-BB82-29B51A97BEB9Q38784790-9405975E-5840-4C07-8387-3B10E58887C9Q38927251-3E1B1B44-33EF-4710-B2F5-86863C1B7928Q38978011-190C51B0-6CC7-4EB0-9FA3-286669456CB8
P2860
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Molecular mechanism of PPARα a ...... alcoholic fatty liver disease.
@en
type
label
Molecular mechanism of PPARα a ...... alcoholic fatty liver disease.
@en
prefLabel
Molecular mechanism of PPARα a ...... alcoholic fatty liver disease.
@en
P1476
Molecular mechanism of PPARα a ...... alcoholic fatty liver disease.
@en
P2093
Philippe Lefebvre
P304
P356
10.1016/J.JHEP.2014.10.039
P577
2014-11-01T00:00:00Z